Beclabuvir hydrochloride
Based on 6 publication(s) in Google Scholar
Beclabuvir (BMS-791325) hydrochloride is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM.
For research use only. We do not sell to patients.
- CAS No.: 958002-36-3
- Formula: C36H46ClN5O5S
- Molecular Weight:696.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Beclabuvir hydrochloride
More- Cell Rep Med. 2026 Mar 9:102646. [Abstract]
- Genomics Proteomics Bioinformatics. 2025 May 10;23(1):qzaf008. [Abstract]
- J Gastroenterol. 2019 May;54(5):449-458. [Abstract]
- Commun Biol. 2021 Jan 20;4(1):93. [Abstract]
- Antiviral Res. 2026 Jun 22:252:106470. [Abstract]
- J Hum Genet. 2020 Jan;65(2):143-153. [Abstract]
All DNA/RNA Synthesis Isoforms
More
Biological Activity
|
RNA Polymerase |
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 958002-36-3
-
Molecular Weight 696.30
-
Formula C36H46ClN5O5S
-
SMILES
O=C(N1C2CCC1CN(C)C2)[C@@]3(CN4C5=C(C6CCCCC6)C7=CC=C(C(NS(=O)(N(C)C)=O)=O)C=C47)[C@H](C8=CC(OC)=CC=C85)C3.Cl
-
Synonyms
BMS-791325 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
Human liver-derived organoids recapitulate Oropouche virus infection and manifestation, enabling antiviral drug discovery. [Abstract]2026 Mar 9:102646. PMID: 41806841 -
Genomics Proteomics Bioinformatics
2025 May 10;23(1):qzaf008. PMID: 39957240 -
J Gastroenterol
Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. [Abstract]2019 May;54(5):449-458. PMID: 30684016 -
Commun Biol
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. [Abstract]2021 Jan 20;4(1):93. PMID: 33473151 -
Antiviral Res
2026 Jun 22:252:106470. PMID: 42331291 -
J Hum Genet
Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir. [Abstract]2020 Jan;65(2):143-153. PMID: 31645655
Purity & Documentation
References
[1]. Gentile I, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111-21. [Content Brief]
[2]. Tatum H, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J Viral Hepat. 2015 Aug;22(8):658-64. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz